Big Pharma Has a Remarkably Effective Business Model
Many of you have observed an explosion of RSV (respiratory syncytial virus, a respiratory virus that frequently afflicts children) and to a lesser extent influenza (e.g. a friend called me up today to ask if it was linked to the vaccine and many colleagues have reached out to me about the unprecedented surge they are observing in patients).
Although I expected this, it is still somewhat disconcerting to see this happen as RSV is typically not a major concern outside of very specific patient populations.
I first started seeing signs of this concerning trend last year when Australia reported a huge spike in RSV over the summer.
This summer, Australia experienced an unprecedented spike in both influenza and RSV. This has led many experts to become worried about the threat we were facing from these diseases and emphasize the urgent need to develop a vaccine for RSV (the last one was pulled because it caused enhanced respiratory disease).